PriceTargets.com logo

PepGen - PEPG Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $16.67
  • Forecasted Upside: 271.20%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.49 As of 11/14/2024 01:00 AM ET
▼ -0.06 (-1.32%)

This chart shows the closing price for PEPG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PepGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PEPG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PEPG

Analyst Price Target is $16.67
▲ +271.20% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for PepGen in the last 3 months. The average price target is $16.67, with a high forecast of $26.00 and a low forecast of $12.00. The average price target represents a 271.20% upside from the last price of $4.49.

This chart shows the closing price for PEPG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 contributing investment analysts is to moderate buy stock in PepGen. This rating has held steady since July 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/19/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/8/2024WedbushLower TargetOutperform ➝ Outperform$19.00 ➝ $12.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
7/31/2024WedbushReiterated RatingOutperform ➝ Outperform$20.00 ➝ $20.00
7/31/2024Bank of AmericaDowngradeBuy ➝ Neutral$12.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$26.00
5/15/2024WedbushReiterated RatingOutperform ➝ Outperform$20.00
3/7/2024WedbushLower TargetOutperform ➝ Outperform$21.00 ➝ $20.00
1/30/2024WedbushReiterated RatingOutperform ➝ Outperform$21.00
9/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$26.00
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$26.00
6/14/2023SVB SecuritiesLower Target$33.00 ➝ $28.00
4/3/2023HC WainwrightReiterated RatingBuy$26.00
3/24/2023WedbushBoost TargetOutperform$17.00 ➝ $22.00
3/24/2023HC WainwrightReiterated RatingBuy$26.00
12/21/2022HC WainwrightInitiated CoverageBuy$26.00
11/10/2022Leerink PartnersLower TargetOutperform$40.00 ➝ $33.00
5/31/2022WedbushInitiated CoverageOutperform$17.00
5/31/2022Stifel NicolausInitiated CoverageBuy$24.00
5/31/2022Leerink PartnersInitiated CoverageOutperform$40.00
5/31/2022Bank of AmericaInitiated CoverageBuy$16.00
(Data available from 11/15/2019 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2024
  • 7 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/16/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/15/2024

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

PepGen logo
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $4.49
Low: $4.43
High: $5.01

50 Day Range

MA: $8.12
Low: $4.49
High: $9.76

52 Week Range

Now: $4.49
Low: $3.81
High: $19.30

Volume

146,577 shs

Average Volume

122,476 shs

Market Capitalization

$146.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of PepGen?

The following equities research analysts have issued research reports on PepGen in the last twelve months: Bank of America Co., HC Wainwright, and Wedbush.
View the latest analyst ratings for PEPG.

What is the current price target for PepGen?

0 Wall Street analysts have set twelve-month price targets for PepGen in the last year. Their average twelve-month price target is $16.67, suggesting a possible upside of 271.2%. HC Wainwright has the highest price target set, predicting PEPG will reach $26.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $12.00 for PepGen in the next year.
View the latest price targets for PEPG.

What is the current consensus analyst rating for PepGen?

PepGen currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PEPG.

What other companies compete with PepGen?

Other companies that are similar to PepGen include Emergent BioSolutions, Y-mAbs Therapeutics, Acelyrin, Larimar Therapeutics and Mereo BioPharma Group. Learn More about companies similar to PepGen.

How do I contact PepGen's investor relations team?

The company's listed phone number is 781-797-0979 and its investor relations email address is [email protected]. The official website for PepGen is www.pepgen.com. Learn More about contacing PepGen investor relations.